GSK (GSK) Stock Price & Analysis
GSK (GSK) rose 1.20% to USD 51.25 as of June 9, 2026 at 23:51 UTC, according to Nexqual real-time market data.
GSK last closed at USD 50.64; the session ranged USD 50.36–51.34 on volume of 6,114,882 shares. Market capitalization is $102.73B, with a 52-week range of USD 35.45–61.7 (NYQ). Source: Nexqual, June 9, 2026 at 23:51 UTC.
Key Statistics (as of June 9, 2026 at 23:51 UTC)
| Price | USD 51.25 |
|---|---|
| Change | ▲ 1.20% (up) |
| Previous Close | USD 50.64 |
| Open | USD 50.43 |
| Day Range | USD 50.36 – 51.34 |
| 52-Week Range | USD 35.45 – 61.7 |
| Volume | 6,114,882 shares |
| Market Cap | $102.73B |
| Exchange | NYQ |
Technical Analysis (GSK)
Nexqual's technical model rates GSK "NEUTRAL" based on 2 bullish and 3 bearish signals across 124 daily candles, as of June 9, 2026 at 23:51 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 46.25 (neutral) |
| vs SMA50 | Below (USD 53.21) |
| MACD | -0.51 (negative) |
Analyst Ratings (GSK)
Wall Street analysts rate GSK "Hold" based on 7 analysts, with a mean price target of USD 56.63 (range USD 47–70), per Nexqual as of June 9, 2026 at 23:51 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 56.63 |
| High Target | USD 70 |
| Low Target | USD 47 |
| Buy / Hold / Sell | 1 / 5 / 1 |
Earnings (GSK)
| Next Earnings Date | 2026-07-28 |
|---|---|
| EPS Estimate | USD 1.25 |
| Revenue Estimate | $8.23B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.26 vs est 1.16 ▲ beat |
| 2025-12-31 | USD 0.7 vs est 0.62 ▲ beat |
| 2025-09-30 | USD 1.46 vs est 1.26 ▲ beat |
| 2025-06-30 | USD 1.24 vs est 1.11 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Financials & Fundamentals (GSK)
| Total Revenue | $32.78B |
|---|---|
| Revenue Growth (YoY) | +1.50% |
| Gross Margin | +72.87% |
| Operating Margin | +36.28% |
| Profit Margin | +17.78% |
| ROE | +40.91% |
| Debt / Equity | 109.7 |
| Current Ratio | 0.79 |
| Total Cash | $3.44B |
| Total Debt | $19.11B |
| Free Cash Flow | $3.02B |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Financial Health Score (GSK)
Nexqual rates GSK's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 23:51 UTC.
| Growth | Mixed — Revenue +4.1% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 73%, operating 36% |
| Balance Sheet | Weak — $3.44B cash vs $19.1B debt |
| Cash Flow | Solid — FCF $3.02B, 9% margin |
| Efficiency | Strong — ROE 41%, ROA 10.0% |
Ownership (GSK)
| Insider Ownership | +0.06% |
|---|---|
| Institutional Ownership | +18.84% |
| Shares Outstanding | 2.00B |
| Float | 1.95B |
| Short % of Float | +0.68% |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Leadership (GSK)
GSK is led by Luke Victor Miels (age 51), CEO & Director, per Nexqual as of June 9, 2026 at 23:51 UTC.
| CEO & Director | Luke Victor Miels (age 51) |
|---|---|
| CFO & Executive Director | Julie Belita Brown A.C.A. (age 63) |
| Chief Scientific Officer and Head of R & D | Tony Wood |
| President of Corporate Development | David Simon Redfern BSc (Hons), CA (age 59) |
Major Backers & Investors (GSK)
Notable institutional backers of GSK include Dodge & Cox Inc., FMR, LLC, Fisher Asset Management, LLC, according to Nexqual as of June 9, 2026 at 23:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 5.23% |
| FMR, LLC | 3.34% |
| Fisher Asset Management, LLC | 1.7% |
| Primecap Management Company | 1.24% |
| Fidelity | 0.96% |
| Acadian Asset Management. LLC | 0.58% |
| Wellington Management | 0.58% |
| Morgan Stanley | 0.54% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.52% |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SNY | Sanofi | USD 44.73 | ▼ 0.64% |
| NVS | Novartis AG | USD 149.12 | ▼ 0.03% |
| AZN | AstraZeneca PLC | USD 183.43 | ▼ 1.36% |
| BMY | Bristol-Myers Squibb Company | USD 56.48 | ▼ 1.38% |
| MRK | Merck & Company, Inc. | USD 119.6 | ▼ 0.99% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:51 UTC. This page is informational and not investment advice.